Get the Stockscreener App
3.80
2.06%
-0.08
After Hours:
3.80
Zentalis Pharmaceuticals Inc stock is traded at $3.80, with a volume of 695.39K.
It is down -2.06% in the last 24 hours and down -17.75% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$3.88
Open:
$3.88
24h Volume:
695.39K
Relative Volume:
0.58
Market Cap:
$359.75M
Revenue:
$26.87M
Net Income/Loss:
$-124.13M
P/E Ratio:
-2.1867
EPS:
-1.7378
Net Cash Flow:
$-125.60M
1W Performance:
-0.65%
1M Performance:
-17.75%
6M Performance:
+59.00%
1Y Performance:
+115.91%
1-Day Range:
$3.72
$3.89
1-Week Range:
$3.72
$3.96
52-Week Range:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.80 | 363.54M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals(ZNTL.US) 10% Shareholder Buys US$15.17 Million in Common Stock - Moomoo
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock - MarketBeat
Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock - Investing.com
Nearly one-fifth of Zentalis (NASDAQ: ZNTL) sits with one investor group - Stock Titan
Zentalis Pharma closes $92.6 million public offering - The Pharma Letter
New Form 4 Open market buy - Moomoo
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals closes $92.6 million stock offering - Investing.com
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Zentalis Pharmaceuticals Announces Closing of Underwritten - GlobeNewswire
GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering - lw.com
symbol__ Stock Quote Price and Forecast - CNN
Why is Zentalis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Why is Zentalis Pharmaceuticals stock tumbling today? - Investing.com
Zentalis Pharmaceuticals Shares Fall on Public Offering Pricing - Moomoo
Zentalis Pharmaceuticals (ZNTL) Prices $80.5M Public Offering to Fund Clinical Trials - GuruFocus
Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 - Investing.com
Zentalis Pharmaceuticals Prices $80.5 Million Public Offering of Common Stock - Quiver Quantitative
Zentalis Sets $3.50 Share Price to Fund Clinical Trials - Stock Titan
Zentalis Pharmaceuticals Announces Pricing Of Underwritten Public Offering - TradingView
Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis - Stock Titan
Zentalis Pharmaceuticals announces public stock offering By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals announces public stock offering - Investing.com
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering - TradingView
Zentalis Pharmaceuticals stock falls on public offering news By Investing.com - Investing.com Nigeria
Zentalis Pharmaceuticals stock falls on public offering news - Investing.com
Mizuho Securities Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Analysts Decrease Earnings Estimates for ZNTL - MarketBeat
Zentalis Pharmaceuticals (ZNTL) Slips to $4.15 Amid Cautious Biotech TradingDemand Zone - dars.gov.et
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Zentalis Pharmaceuticals(ZNTL.US) With Hold Rating, Raises Target Price to $5 - Moomoo
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Highlights Q2 Results and Azenosertib Progress - The Globe and Mail
Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside - TradingView
Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating - marketscreener.com
Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results - MarketBeat
ZNTL Advances Clinical Trials for Ovarian Cancer Drug Amid Valua - GuruFocus
Zentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary - TradingView
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Zentalis Q2 FY26 net loss widens to $42.29 million - Bitget
ZNTL: Clinical and regulatory progress advances, with $174.6M cash runway into late 2027 despite higher losses - TradingView
ZNTL: Q2 2026 net loss widened to $42.3M as R&D spending rose for late-stage azenosertib trials - TradingView
BlackRock, Inc. Expands Stake in Zentalis Pharmaceuticals (ZNTL) with Strategic Share Addition - GuruFocus
ZNTL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '26 |
Sale |
2.43 |
2,962 |
7,197 |
33,667 |
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
8.37%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):